

## Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS 1 Web Page for STN Seminar Schedule - N. America  
NEWS 2 JUL 02 LMEDLINE coverage updated  
NEWS 3 JUL 02 SCISEARCH enhanced with complete author names  
NEWS 4 JUL 02 CHEMCATS accession numbers revised  
NEWS 5 JUL 02 CA/CAplus enhanced with utility model patents from China  
NEWS 6 JUL 16 CAplus enhanced with French and German abstracts  
NEWS 7 JUL 18 CA/CAplus patent coverage enhanced  
NEWS 8 JUL 26 USPATFULL/USPAT2 enhanced with IPC reclassification  
NEWS 9 JUL 30 USGENE now available on STN  
NEWS 10 AUG 06 CAS REGISTRY enhanced with new experimental property tags  
NEWS 11 AUG 06 FSTA enhanced with new thesaurus edition  
NEWS 12 AUG 13 CA/CAplus enhanced with additional kind codes for granted patents  
NEWS 13 AUG 20 CA/CAplus enhanced with CAS indexing in pre-1907 records  
NEWS 14 AUG 27 Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB  
NEWS 15 AUG 27 USPATOLD now available on STN  
NEWS 16 AUG 28 CAS REGISTRY enhanced with additional experimental spectral property data  
NEWS 17 SEP 07 STN AnaVist, Version 2.0, now available with Derwent World Patents Index  
NEWS 18 SEP 13 FORIS renamed to SOFIS  
NEWS 19 SEP 13 INPADOCDB enhanced with monthly SDI frequency  
NEWS 20 SEP 17 CA/CAplus enhanced with printed CA page images from 1967-1998  
NEWS 21 SEP 17 CAplus coverage extended to include traditional medicine patents  
NEWS 22 SEP 24 EMBASE, EMBAL, and LEMBASE reloaded with enhancements  
NEWS 23 OCT 02 CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt  
NEWS 24 OCT 19 BEILSTEIN updated with new compounds  
  
NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.  
  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS DATES

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 17:57:34 ON 07 NOV 2007

FILE 'REGISTRY' ENTERED AT 17:57:45 ON 07 NOV 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 6 NOV 2007 HIGHEST RN 952567-23-6  
DICTIONARY FILE UPDATES: 6 NOV 2007 HIGHEST RN 952567-23-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.



TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>  
Uploading C:\Program Files\Stnexp\Queries\10564709a.str



```
chain nodes :  
7 9 10 11 12  
ring nodes :  
1 2 3 4 5 6  
chain bonds :  
2-11 3-10 4-7 5-9 6-12  
ring bonds :  
1-2 1-6 2-3 3-4 4-5 5-6  
exact/norm bonds :  
4-7 6-12  
exact bonds :  
1-2 1-6 2-3 2-11 3-4 3-10 4-5 5-6 5-9  
isolated ring systems :  
containing 1 :
```


G1:C,H

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 9:CLASS 10:CLASS  
11:CLASS 12:CLASS

L1 STRUCTURE UPLOADED

=> d 11  
L1 HAS NO ANSWERS  
L1 STR



G1 C,H

Structure attributes must be viewed using STN Express query preparation.

=> s 11  
SAMPLE SEARCH INITIATED 17:58:02 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 9138 TO ITERATE

21.9% PROCESSED 2000 ITERATIONS 50 ANSWERS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 177031 TO 188489  
PROJECTED ANSWERS: 8196 TO 10810

L2 50 SEA SSS SAM L1

=> s 11 full  
FULL SEARCH INITIATED 17:58:09 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 183338 TO ITERATE

100.0% PROCESSED 183338 ITERATIONS 8649 ANSWERS  
SEARCH TIME: 00.00.01

L3 8649 SEA SSS FUL L1

=> file caplus  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
ENTRY SESSION  
FULL ESTIMATED COST 172.10 172.31

FILE 'CAPLUS' ENTERED AT 17:58:15 ON 07 NOV 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is

held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Nov 2007 VOL 147 ISS 20  
FILE LAST UPDATED: 6 Nov 2007 (20071106/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13/prep full  
57856 L3  
4486206 PREP/RL  
L4 3550 L3/PREP  
(L3 (L) PREP/RL)

=> s 14 and py<2003  
22908262 PY<2003  
L5 3013 L4 AND PY<2003

=> s 15 and nickel  
654925 NICKEL  
205 NICKELS  
654956 NICKEL  
(NICKEL OR NICKELS)  
L6 17 L5 AND NICKEL

=> d ibib abs hitstr tot

L6 ANSWER 1 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2005:15791 CAPLUS  
DOCUMENT NUMBER: 142:120462  
TITLE: Therapeutic and diagnostic conjugates for use with  
multispecific antibodies  
INVENTOR(S): McBride, William J.; Goldenberg, David M.; Noren,  
Carl; Hansen, Hans J.  
PATENT ASSIGNEE(S): Immunomedics, Inc., USA  
SOURCE: U.S. Pat. Appl. Publ., 53 pp., Cont.-in-part of U.S.  
Ser. No. 150,654.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 19  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005002945	A1	20050106	US 2004-776470	20040211
US 7074405	B1	20060711	US 1999-337756	19990622
US 7052872	B1	20060530	US 1999-382186	19990823
US 2002006379	A1	20020117	US 2001-823746	20010403 <--
US 6962702	B2	20051108		
US 2003198595	A1	20031023	US 2002-150654	20020517
US 7138103	B2	20061121		
AU 2005211754	A1	20050825	AU 2005-211754	20050211
CA 2555666	A1	20050825	CA 2005-2555666	20050211
WO 2005077071	A2	20050825	WO 2005-US4177	20050211

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1720575	A2	20061115	EP 2005-726492	20050211
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
JP 2007528372	T	20071011	JP 2006-553216	20050211
PRIORITY APPLN. INFO.:				
			US 1998-90142P	P 19980622
			US 1998-104156P	P 19981014
			US 1999-337756	A2 19990622
			US 1999-382186	B2 19990823
			US 2001-823746	A2 20010403
			US 2002-150654	A2 20020517
			US 2004-776470	A 20040211
			WO 2005-US4177	W 20050211

OTHER SOURCE(S): MARPAT 142:120462

AB Disclosed are compds. that include two or more haptens conjugated by a spacer or a carrier. The haptens may include diethylenetriaminepentaacetate (DTPA), histamine-succinyl-glutamine (HSG), or combinations of DTPA and HSG. The compds. also includes an effector mol. which may be conjugated to one or more of the haptens, the spacer/carrier, or both. The effector mol. may be conjugated by a number of linkages including an ester linkage, an imino linkage, an amino linkage, a sulfide linkage, a thiosemicarbazone linkage, a semicarbazone linkage, an oxime linkage, an ether linkage, or combinations of these linkages. Also disclosed are methods of synthesizing the compds. and/or precursors of the compds.

IT 616208-30-1DP, complexes with Indium III 616208-30-1P

RL: DGN (Diagnostic use); PKT (Pharmacokinetics); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)



(therapeutic and diagnostic conjugates for use with multispecific antibodies)

RN 616208-30-1 CAPLUS

CN L-Lysinamide, N2-[4-[[1-[(2S,4S)-4-[(3-amino-2,3,6-trideoxy- $\alpha$ -L-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]-2-hydroxyethylidene]hydrazino]benzoyl]-N6-[N-[2-[(2-[bis(carboxymethyl)amino]ethyl](carboxymethyl)amino]ethyl]-N-(carboxymethyl)glycyl]-L-lysyl-L-tyrosyl-N6-[N-[2-[(2-[bis(carboxymethyl)amino]ethyl)(carboxymethyl)amino]ethyl]-N-(carboxymethyl)glycyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.





RN 616208-30-1 CAPLUS

CN L-Lysinamide, N2-[4-[(1-[(2S,4S)-4-[(3-amino-2,3,6-trideoxy- $\alpha$ -L-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]-2-hydroxyethylidene]hydrazino]benzoyl]-N6-[N-[2-[(2-[bis(carboxymethyl)amino]ethyl)(carboxymethyl)amino]ethyl]-N-(carboxymethyl)glycyl]-L-lysyl-L-tyrosyl-N6-[N-[2-[(2-[bis(carboxymethyl)amino]ethyl)(carboxymethyl)amino]ethyl]-N-(carboxymethyl)glycyl]- (9CI) (CA INDEX NAME)



Absolute stereochemistry.

Double bond geometry unknown.



L6 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2002:444528 CAPLUS  
 DOCUMENT NUMBER: 137:30253  
 TITLE: Metalloligands for cleaving nucleic acids  
 INVENTOR(S): Cowan, James A.  
 PATENT ASSIGNEE(S): The Ohio State University Research Foundation, USA  
 SOURCE: U.S., 8 pp.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6403777	B1	20020611	US 1999-348225	19990706 <--
PRIORITY APPLN. INFO.:			US 1999-348225	19990706
OTHER SOURCE(S):	MARPAT 137:30253			
GI				




AB Transition metal complexes, referred to hereinafter as "metalloligands", that catalyze the degradation of DNA and the cleavage of RNA at select sites are provided. In one embodiment, the metalloligand has structure I (R1 = amino group, i.e. NH, or alkylamino group comprising 1 or 2 carbon atoms; R2 = amino group, hydroxyl group, alkylamino group comprising 1 or 2 carbon atoms, alkylhydroxyl group comprising 1 or 2 carbon atoms; J = ligand which comprises at least one carbon-containing five-membered or six-membered ring structure; and M = transition metal ion which is bound via coordinate bonds to R1 and R2). In another embodiment the metalloligand has structure II (R1' and R1'' = amino group or an alkylamino group comprising 1 or 2 carbon atoms; R2' and R2'' = the same or different and R2' and R2'' = amino group, hydroxyl group, alkylamino group comprising 1 or 2 carbon atoms, alkylhydroxyl group comprising one or two carbon atoms; J' and J'' = ligands which comprise at least one carbon-containing five-membered or six-membered ring structure; M = transition metal ion which is bound via coordinate bonds to R1', R1'', R2' and R2''). Methods of cleaving nucleic acids using the metalloligands are also provided. A 23-mer RNA with a stem-loop motif was selectively cleaved by Cu(kanamycin A), prepared by reacting kanamycin A sulfate and CuSO<sub>4</sub>.

IT 59-01-8DP, Kanamycin A, complexes with transition metal ions  
 4696-76-8DP, Kanamycin B, complexes with transition metal ions  
 32986-56-4DP, Tobramycin, complexes with transition metal ions  
 RL: CAT (Catalyst use); SPN (Synthetic preparation); PREP (Preparation); USES (Uses)  
 (metalloligands for cleaving nucleic acids)

RN 59-01-8 CAPLUS

CN D-Streptamine, O-3-amino-3-deoxy- $\alpha$ -D-glucopyranosyl-(1 $\rightarrow$ 6)-O-[6-amino-6-deoxy- $\alpha$ -D-glucopyranosyl-(1 $\rightarrow$ 4)]-2-deoxy- (CA INDEX NAME)

Absolute stereochemistry.




RN 4696-76-8 CAPLUS

CN D-Streptamine, O-3-amino-3-deoxy- $\alpha$ -D-glucopyranosyl-(1 $\rightarrow$ 6)-O-

[2,6-diamino-2,6-dideoxy- $\alpha$ -D-glucopyranosyl-(1 $\rightarrow$ 4)]-2-deoxy-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 32986-56-4 CAPLUS

CN D-Streptamine, O-3-amino-3-deoxy- $\alpha$ -D-glucopyranosyl-(1 $\rightarrow$ 6)-O-[2,6-diamino-2,3,6-trideoxy- $\alpha$ -D-ribo-hexopyranosyl-(1 $\rightarrow$ 4)]-2-deoxy- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:935443 CAPLUS

DOCUMENT NUMBER: 136:58849

TITLE: Compositions and methods to improve the oral absorption of antimicrobial agents

INVENTOR(S): Choi, Seung-Ho; Lee, Jeoung-Soo; Keith, Dennis

PATENT ASSIGNEE(S): Cubist Pharmaceuticals, Inc., USA; International Health Management Associates, Inc.; University of Utah Research Foundation

SOURCE: PCT Int. Appl., 70 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----
WO 2001097851	A2	20011227	WO 2001-US19625	20010618 <--
WO 2001097851	A3	20020516		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,				

RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,				
UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6248360	B1	20010619	US 2000-598089	20000621 <--
CA 2413251	A1	20011227	CA 2001-2413251	20010618 <--
EP 1294361	A2	20030326	EP 2001-944619	20010618
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001012393	A	20030708	BR 2001-12393	20010618
JP 2003535911	T	20031202	JP 2002-503335	20010618
NZ 523276	A	20050225	NZ 2001-523276	20010618
RU 2282462	C2	20060827	RU 2003-101402	20010618
US 2003039956	A1	20030227	US 2001-888114	20010622
MX 2002PA12670	A	20031006	MX 2002-PA12670	20021218
US 2000-598089 A 20000621				
US 2001-829405 A 20010409				
US 2001-283976P P 20010416				
WO 2001-US19625 W 20010618				
PRIORITY APPLN. INFO.:				

AB The present invention provides compns. and methods for increasing absorption of antibacterial agents, particularly third generation cephalosporin antibacterial agents, in oral dosage solid and/or suspension forms. Specifically, the composition is comprised of a biopolymer that is preferably swellable and/or mucoadhesive, an antimicrobial agent, and a cationic binding agent contained within the biopolymer such that the binding agent is ionically bound or complexed to at least one member selected from the group consisting of the biopolymer and the antimicrobial agent. A solution of 44.5 mg calcium chloride in 10 mL water and 1.0 g of ceftriaxone in 10 mL water was added gradually to a solution of 400 mg carrageenan and the dispersion was centrifuged and the supernatant was lyophilized. The resulting composition comprised carrageenan 27.7, ceftriaxone 1, and calcium chloride 3.1%. Plasma concentration of different antimicrobial-biopolymer complexes after oral administration to rats was measured.

IT 1404-90-6DP, Vancomycin, conjugates with biopolymers and cationic binding agents 32986-56-4DP, Tobramycin, conjugates with biopolymers and cationic binding agents 37517-28-5DP, Amikacin, conjugates with biopolymers and cationic binding agents 171099-57-3DP, Oritavancin, conjugates with biopolymers and cationic binding agents


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(compns. and methods to improve oral absorption of antimicrobial agents)


RN 1404-90-6 CAPLUS

CN Vancomycin (CA INDEX NAME)

Absolute stereochemistry.




-Bu-i



RN 32986-56-4 CAPLUS

CN D-Streptamine, O-3-amino-3-deoxy- $\alpha$ -D-glucopyranosyl-(1 $\rightarrow$ 6)-O-[2,6-diamino-2,3,6-trideoxy- $\alpha$ -D-ribo-hexopyranosyl-(1 $\rightarrow$ 4)]-2-deoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 37517-28-5 CAPLUS

CN D-Streptamine, O-3-amino-3-deoxy- $\alpha$ -D-glucopyranosyl-(1 $\rightarrow$ 6)-O-[6-amino-6-deoxy- $\alpha$ -D-glucopyranosyl-(1 $\rightarrow$ 4)]-N1-[(2S)-4-amino-2-hydroxy-1-oxobutyl]-2-deoxy- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 171099-57-3 CAPLUS


CN Vancomycin, 22-O-(3-amino-2,3,6-trideoxy-3-C-methyl-alpha-L-arabinopyranosyl)-N3''-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-, (4''R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 1-B



PAGE 2-A

Cl—






L6 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2001:265367 CAPLUS  
 DOCUMENT NUMBER: 134:280645  
 TITLE: Process for preparing tetracyclic intermediates useful  
 in the synthesis of anthracyclines  
 INVENTOR(S): Chen, Qing Ping; Woods, Ross Alexander; Elliott, Robyn  
 Louise  
 PATENT ASSIGNEE(S): Institute of Drug Technology Australia Limited,  
 Australia  
 SOURCE: PCT Int. Appl., 41 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001025179	A1	20010412	WO 2000-AU1198	20000929 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: AU 1999-3197 A 19991001  
 OTHER SOURCE(S): MARPAT 134:280645  
 GI



I


AB Tetracyclic derivs. such as I [R1 = X-(C=X)-Y; X = O, S; Y = NR1R2, OR3, R4; R1,R2 = alkyl, aryl, aralkyl; R3 = alkyl, aryl, aralkyl; R4 = alkyl, alkenyl, alkynyl, aryl, aralkyl; R = H, protected OH], useful in the synthesis of anthracyclines were prepared by rearrangement of thiono ester derivs. followed by reduction

IT 20830-81-3P, Daunomycin  
 RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of tetracyclic intermediates useful in the synthesis of anthracyclines)

RN 20830-81-3 CAPLUS

CN 5,12-Naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy- $\alpha$ -L-lyxohexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2000:756549 CAPLUS  
 DOCUMENT NUMBER: 133:319052  
 TITLE: Sortase-transamidases from Gram-positive bacteria and their uses for drug screening and peptide and protein display  
 INVENTOR(S): Schneewind, Olaf; Mazmanian, Sarkis; Liu, Gwen; Ton-That, Hung  
 PATENT ASSIGNEE(S): Regents of the University of California, USA  
 SOURCE: PCT Int. Appl., 126 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM: COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000062804	A2	20001026	WO 2000-US10198	20000413 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2365523	A1	20001026	CA 2000-2365523	20000413 <--
EP 1233780	A1	20020828	EP 2000-922254	20000413 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
JP 2003506011	T	20030218	JP 2000-611940	20000413
AU 784043	B2	20060119	AU 2000-42468	20000413
US 2005069984	A1	20050331	US 2004-968317	20041018
US 7238489	B2	20070703		

PRIORITY APPLN. INFO.: US 1999-292437 A 19990415  
WO 2000-US10198 W 20000413

AB The present invention is directed to sortase-transamidase enzymes from gram-pos. bacteria, particularly the products of the surface protein sorting (srtA) gene of *Staphylococcus aureus*, and methods for their use, particularly in the areas of drug screening and peptide and protein display. Amino acid and nucleotide sequences are provided for the enzyme and srtA gene from *S. aureus*. Typically, the gram-pos. bacterium is a species selected from the group *Staphylococcus aureus*, *Streptococcus pyogenes*, *Actinomyces naeslundii*, *Enterococcus faecalis*, *Streptococcus mutans*, *Streptococcus pneumoniae*, and *Bacillus subtilis*. The Sortase-transamidase enzyme catalyzes a reaction that covalently crosslinks the C-terminus of a protein having a sorting signal to the peptidoglycan of a gram-pos. bacterium, the sorting signal having a motif of LPX3X4G therein, wherein sorting occurs by cleavage between the forth and fifth residues of the LPX3X4G motif. An assay for sortase-transamidase can be performed by monitoring the capture of a soluble peptide that is a substrate for the enzyme by its interaction with an affinity resin. Sortase-transamidase is a target for antibiotic action. In addition, its crosslinking activity can be used for protein and peptide display on the surface of gram-pos. bacteria, and sorted mols. can be used for the diagnosis and treatment of bacterial infections and for the production of vaccines.


IT 1404-90-6DP, Vancomycin, conjugates with proteins  
32986-56-4DP, Tobramycin, conjugates with proteins  
37517-28-5DP, Amikacin, conjugates with proteins  
RL: BPN (Biosynthetic preparation); BUU (Biological use, unclassified);  
THU (Therapeutic use); BIOL (Biological study); PREP (Preparation)  
; USES (Uses)  
(for surface display or diagnosis or treatment; sortase-transamidases from gram-pos. bacteria and their uses for drug screening and peptide and protein display)

RN 1404-90-6 CAPLUS

CN Vancomycin (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


—Bu-i



RN 32986-56-4 CAPLUS

CN D-Streptamine, O-3-amino-3-deoxy- $\alpha$ -D-glucopyranosyl-(1 $\rightarrow$ 6)-O-[2,6-diamino-2,3,6-trideoxy- $\alpha$ -D-ribo-hexopyranosyl-(1 $\rightarrow$ 4)]-2-deoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 37517-28-5 CAPLUS

CN D-Streptamine, O-3-amino-3-deoxy- $\alpha$ -D-glucopyranosyl-(1 $\rightarrow$ 6)-O-[6-amino-6-deoxy- $\alpha$ -D-glucopyranosyl-(1 $\rightarrow$ 4)]-N1-[(2S)-4-amino-2-hydroxy-1-oxobutyl]-2-deoxy- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).




L6 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:34955 CAPLUS  
 DOCUMENT NUMBER: 132:90364  
 TITLE: Metalloligands for cleaving nucleic acids  
 INVENTOR(S): Cowan, James A.  
 PATENT ASSIGNEE(S): The Ohio State Research Foundation, USA  
 SOURCE: PCT Int. Appl., 20 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000001797	A2	20000113	WO 1999-US15195	19990706 <--
W: AU, CA, JP RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9949700	A	20000124	AU 1999-49700 US 1998-91862P WO 1999-US15195	19990706 <-- P 19980706 W 19990706
OTHER SOURCE(S): MARPAT 132:90364 GI				



I



II

AB Transition metal complexes, referred to hereinafter as "metalloligands", that catalyze the degradation of DNA and the cleavage of RNA at selected sites are provided. In one embodiment, the metalloligand has structure I, wherein R1 is an amino group, i.e. an NH, or an alkylamino group comprising 1 or 2 carbon atoms; wherein R2 is selected from the group consisting of an amino group, a hydroxyl group, i.e., O(H), an alkylamino group comprising 1 or 2 carbon atoms; and an alkylhydroxyl group comprising 1 or 2 carbon atoms; wherein J is a ligand which comprises at least one carbon-containing five-membered or six-membered ring structure; and wherein M is a transition metal ion which is bound via coordinate bonds to R1 and R2. In another embodiment the metalloligand has structure II, wherein R1' and R1'' are the same or different and wherein R1' and R1'' are an amino group or an alkylamino group comprising 1 or 2 carbon atoms; wherein R2' and R2'' are the same or different and wherein R2' and R2'' are selected from the group consisting of an amino group, a hydroxyl group, an alkylamino group comprising 1 or 2 carbon atoms, and an alkylhydroxyl group consisting one or two carbon atoms; wherein J' and J'' are the same or different and wherein J' and J'' are ligands which comprise at least one carbon-containing five-membered or six-membered ring structure; and wherein M is a transition metal ion which is bound via coordinate bonds to R1', R1'', R2' and R2''. Thus, complexes of Cu<sup>2+</sup> with kanamycin A, neomycin B, and neamine are prepared. Methods of cleaving nucleic acids using the metalloligands are also provided.

IT 59-01-8DP, Kanamycin A, complexes with transition metals

4696-76-8DP, Kanamycin B, complexes with transition metals

32986-56-4DP, Tobramycin, complexes with transition metals


RL: CAT (Catalyst use); SPN (Synthetic preparation); PREP (Preparation); USES (Uses)

(metalloligands for cleaving nucleic acids)

RN 59-01-8 CAPLUS

CN D-Streptamine, O-3-amino-3-deoxy- $\alpha$ -D-glucopyranosyl-(1 $\rightarrow$ 6)-O-[6-amino-6-deoxy- $\alpha$ -D-glucopyranosyl-(1 $\rightarrow$ 4)]-2-deoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 4696-76-8 CAPLUS

CN D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1->6)-O-[2,6-diamino-2,6-dideoxy-alpha-D-glucopyranosyl-(1->4)]-2-deoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 32986-56-4 CAPLUS

CN D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1->6)-O-[2,6-diamino-2,3,6-trideoxy-alpha-D-ribo-hexopyranosyl-(1->4)]-2-deoxy- (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1997:544043 CAPLUS

DOCUMENT NUMBER: 127:220974

TITLE: New technology for the synthesis of vancomycin-type biaryl ring systems

AUTHOR(S): Nicolaou, K. C.; Chu, Xin-Jie; Ramanjulu, Joshi M.; Natarajan, Swaminathan; Brase, Stefan; Rubsam, Frank; Boddy, Christopher N. C.

CORPORATE SOURCE: Department Chemistry, Skaggs Institute Chemical Biology Scripps Research Institute, La Jolla, CA,

SOURCE:

92037, USA  
Angewandte Chemie, International Edition in English (1997), 36(13/14), 1539-1540  
CODEN: ACIEAY; ISSN: 0570-0833

PUBLISHER:

Wiley-VCH


DOCUMENT TYPE:

Journal

LANGUAGE:

English

GI



I

AB A new direct approach with mild reaction conditions for synthesizing the 12-membered biaryl ring system of the antibiotic vancomycin is reported. The key step is the Ni0-mediated [(Ph3P)4Ni is generated in situ] intramol. cyclization of depsipeptides to form biaryl models I (X = O, R1 = R2 = R3 = H; X = O, R1 = H, R2 = R3 = OMe; X = O, R1 = Me, R2 = R3 = OMe; X = NH, R1 = H, R2 = R3 = OMe) of vancomycin.

IT 1404-90-6DP, Vancomycin, biaryl ring models

RL: SPN (Synthetic preparation); PREP (Preparation)


(synthesis of vancomycin-type biaryl ring systems under mild conditions)

RN 1404-90-6 CAPLUS


CN Vancomycin (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



- Bu-i




REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 1993:572865 CAPLUS  
 DOCUMENT NUMBER: 119:172865  
 TITLE: Preparation and characterization of manganese(II), cobalt(II), nickel(II), copper(II) and zinc(II) kanamycin complexes  
 AUTHOR(S): Mashaly, A.  
 CORPORATE SOURCE: Fac. Sci., Menoufia Univ., Shebin El-Kom, Egypt  
 SOURCE: Polyhedron (1993), 12(7), 745-8  
 CODEN: PLYHDE; ISSN: 0277-5387  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB [M2L(SO<sub>4</sub>)<sub>2</sub>(H<sub>2</sub>O)<sub>x</sub>].nH<sub>2</sub>O (M = Mn, Co, Ni, Cu, Zn; L = kanamycin; x = 4, 2, 2, 4, 0; n = 3, 2, 2, 6, 4, resp.) were synthesized and characterized by elemental anal., IR, <sup>1</sup>H NMR, electronic, and ESR spectra to elucidate their structures. The spectral results indicate octahedral geometry around Mn, Co, and Ni, distorted octahedral geometry around Cu, and tetrahedral geometry around Zn.  
 IT 150152-22-0P 150152-25-3P  
 RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation and ESR and IR and visible spectra of)  
 RN 150152-22-0 CAPLUS  
 CN Manganese, [ $\mu$ -[O-3-amino-3-deoxy- $\alpha$ -D-glucopyranosyl-(1 $\rightarrow$ 6)-O-[6-amino-6-deoxy- $\alpha$ -D-glucopyranosyl-(1 $\rightarrow$ 4)]-2-deoxy-D-streptamine]tetraaquabis[sulfato(2 $\rightarrow$ )-O, O']di-, trihydrate, stereoisomer (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

● 3 H<sub>2</sub>O


RN 150152-25-3 CAPLUS  
 CN Copper, [ $\mu$ -[O-3-amino-3-deoxy- $\alpha$ -D-glucopyranosyl-(1 $\rightarrow$ 6)-O-[6-amino-6-deoxy- $\alpha$ -D-glucopyranosyl-(1 $\rightarrow$ 4)]-2-deoxy-D-streptamine]tetraaquabis[sulfato(2 $\rightarrow$ )-O, O']di-, hexahydrate, stereoisomer (9CI) (CA INDEX NAME)

PAGE 1-A




● 6 H<sub>2</sub>O

IT 150152-23-1P 150152-24-2P 150152-26-4P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation and IR and visible spectra of)  
 RN 150152-23-1 CAPLUS  
 CN Cobalt, [ $\mu$ -[O-3-amino-3-deoxy- $\alpha$ -D-glucopyranosyl-(1 $\rightarrow$ 6)-O-[6-amino-6-deoxy- $\alpha$ -D-glucopyranosyl-(1 $\rightarrow$ 4)]-2-deoxy-D-streptamine]tetraaquabis[sulfato(2-)-O,O']di-, dihydrate, stereoisomer (9CI) (CA INDEX NAME)


● 2 H<sub>2</sub>O

RN 150152-24-2 CAPLUS  
 CN Nickel, [ $\mu$ -[O-3-amino-3-deoxy- $\alpha$ -D-glucopyranosyl-(1 $\rightarrow$ 6)-O-[6-amino-6-deoxy- $\alpha$ -D-glucopyranosyl-(1 $\rightarrow$ 4)]-2-deoxy-D-streptamine]tetraaquabis[sulfato(2-)-O,O']di-, dihydrate, stereoisomer (9CI) (CA INDEX NAME)




● 2 H<sub>2</sub>O

RN 150152-26-4 CAPLUS  
CN Zinc, [ $\mu$ -[O-3-amino-3-deoxy- $\alpha$ -D-glucopyranosyl-(1 $\rightarrow$ 6)-O-[6-amino-6-deoxy- $\alpha$ -D-glucopyranosyl-(1 $\rightarrow$ 4)]-2-deoxy-D-streptamine]bis[sulfato(2 $\rightarrow$ 0,0')] $\mu$ di-, tetrahydrate, stereoisomer (9CI) (CA INDEX NAME)




● 4 H<sub>2</sub>O

DOCUMENT NUMBER: 115:280397  
 TITLE: Synthesis and properties of methyl  
 3-acetamido-3,6-dideoxy- $\alpha$ -L-glucopyranoside  
 AUTHOR(S): Paramonov, N. A.; Knirel, Yu. A.; Kochetkov, N. K.  
 CORPORATE SOURCE: N. D. Zelinskii Inst. Org. Chem., Moscow, USSR  
 SOURCE: Bioorganicheskaya Khimiya (1991), 17(8),  
 1111-15  
 DOCUMENT TYPE: CODEN: BIKHD7; ISSN: 0132-3423  
 Journal  
 LANGUAGE: Russian  
 OTHER SOURCE(S): CASREACT 115:280397  
 GI



AB The title compound I [R = MeC(:NH)NH] (II) was prepared in 2 steps from nitro compound I (R = NO<sub>2</sub>) by reduction with N<sub>2</sub>H<sub>4</sub>.H<sub>2</sub>O in the presence of Rancy Ni followed by treatment with MeC(:NH)OEt.HCl. Treating II with Et<sub>3</sub>N gave 80% acetamide derivative I (R = AcNH); reducing II by LiBH<sub>4</sub> gave 75% amine I (R = EtNH).  
 IT 5817-28-7P  
 RN 5817-28-7 CAPLUS

CN  $\alpha$ -L-Glucopyranoside, methyl 3-amino-3,6-dideoxy- (9CI) (CA INDEX NAME)  
 Absolute stereochemistry.



L6 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 1991:608354 CAPLUS  
 DOCUMENT NUMBER: 115:208354  
 TITLE: Enzymic-chemical modification of kanamycin B  
 AUTHOR(S): Wu, Ronghui; Zhu, Baoquan; Su, Shenghui  
 CORPORATE SOURCE: Shanghai Inst. Pharm. Ind., Shanghai, 200040, Peop. Rep. China  
 SOURCE: Zhongguo Kangshengsu Zazhi (1991), 16(2), 79-82  
 DOCUMENT TYPE: CODEN: ZKZAEY; ISSN: 1001-8689  
 LANGUAGE: Journal  
 Chinese  
 AB A promising method for selective modification of kanamycin B at the C-3' position by enzymic and chemical processes is reported. Kanamycin B was phosphorylated by the enzyme from the kanamycin B-resistant mutant *E. coli* K12 ML1629 to its 3'-phosphate (I). Reaction of (I) with Me<sub>3</sub>SiCl and Ph<sub>3</sub>P

in a sealed tube gave, after hydrolysis, 3'-chloro-3'-deoxykanamycin B which was hydrogenated with Raney nickel to yield 3'-deoxykanamycin B (II). Fermentation with *E. coli* K12 ML1629, optimal pH of the enzyme reaction, selection of buffer, concentration of ATP, and reaction duration were investigated. Also the chlorination of (I) and selection of catalyst in hydrogenolysis were explored. All compds. described herein were separated and purified by column chromatog. and preparative TLC and were confirmed by MS, NMR, IR spectra and elementary anal. Antimicrobial activity showed that II, i. e., tobramycin, was more effective than kanamycin B against the kanamycin-resistant mutant *E. coli* K12 ML1629.


IT 32986-56-4P, Tobramycin

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of, by enzymic-chemical method)

RN 32986-56-4 CAPLUS

CN D-Streptamine, O-3-amino-3-deoxy- $\alpha$ -D-glucopyranosyl-(1 $\rightarrow$ 6)-O-[2,6-diamino-2,3,6-trideoxy- $\alpha$ -D-ribo-hexopyranosyl-(1 $\rightarrow$ 4)]-2-deoxy- (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

1987:637214 CAPLUS

DOCUMENT NUMBER:

107:237214

TITLE:

Novel synthesis of amikacin

INVENTOR(S):

Mangia, Alberto; Giobbio, Vincenzo; Ornato, Giorgio

PATENT ASSIGNEE(S):

Pierrel S.p.A., Italy

SOURCE:

Eur. Pat. Appl., 11 pp.

CODEN: EPXXDW

DOCUMENT TYPE:

Patent

LANGUAGE:

English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 218292	A1	19870415	EP 1986-201663	19860925 <--
EP 218292	B1	19900808		
R: AT, BE, CH, DE, FR, GB, IT, LI, NL, SE				
HU 43084	A2	19870928	HU 1986-2726	19860630 <--
HU 196421	B	19881128		
DD 258991	A1	19880810	DD 1986-292400	19860711 <--
PL 147396	B1	19890531	PL 1986-260615	19860714 <--
CS 257292	B2	19880415	CS 1986-5913	19860807 <--
AT 55391	T	19900815	AT 1986-201663	19860925 <--
ZA 8607440	A	19870624	ZA 1986-7440	19860930 <--
US 4902790	A	19900220	US 1986-914451	19861002 <--
DK 8604751	A	19870411	DK 1986-4751	19861003 <--
DK 166829	B1	19930719		
CA 1296331	C	19920225	CA 1986-520035	19861007 <--
NO 8604011	A	19870413	NO 1986-4011	19861008 <--
NO 165297	B	19901015		

NO 165297	C 19910123	AU 1986-63633	19861009 <--
AU 8663633	A 19870416		
AU 603998	B2 19901206		
JP 62093297	A 19870428	JP 1986-239398	19861009 <--
JP 02012958	B 19900330		
SU 1771477	A3 19921023	SU 1986-4028258	19861009 <--
PRIORITY APPLN. INFO.:		IT 1985-22425	A 19851010
		EP 1986-201663	A 19860925

GI



AB The title compound (I) was prepared by regioselective acylation of kanamycin A, protected in the 3- and 6'-positions, by treating the latter with a bivalent salt of Zn, Ni, Fe, Co, Mn, Cu, or Cd or their mixts., and treating the resulting unisolated complex with an activated ester derivative of protected L-(-)-H2NCH2CH2CH(OH)CO2H. 3,6'-Di-N-benzyloxycarbonylkanamycin A (II) (5.87 mmol) and 3.9 g Zn(OAc)2 were stirred 2 h at room temperature in Me2SO/H2O (25:75 volume%), followed by addition of


(L)-(-)-PhCH2O2CNHCH2CH2CH(OH)CO2H ester with N-hydroxysuccinimide dissolved in CH2Cl2. The mixture was stirred 5 h and treated with NH4OH to give 51.4% protected I and 16.8% II. A portion of the total product was hydrogenated in aqueous HCO2H over Pd/C to give an aqueous solution containing

6.61 mg I/mL, 0.4 mg/mL kanamycin A, 1.83 mg/mL of diacylated product and 0.21 mg/mL of a second monoacylated product.

IT 66567-34-8P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and deprotection of)


RN 66567-34-8 CAPLUS

CN D-Streptamine, O-3-amino-3-deoxy- $\alpha$ -D-glucopyranosyl-(1 $\rightarrow$ 6)-O-[6-deoxy-6-[[phenylmethoxy]carbonyl]amino]- $\alpha$ -D-glucopyranosyl-(1 $\rightarrow$ 4)]-2-deoxy-N1-[2-hydroxy-1-oxo-4-[[phenylmethoxy]carbonyl]aminobutyl]-N3-[(phenylmethoxy)carbonyl]-, (S)- (9CI) (CA INDEX NAME)

—CH<sub>2</sub>—Ph

IT 37517-28-5P, Amikacin 39831-55-5P, Amikacin sulfate  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of, by regioselective acylation of protected kanamycin A  
 derivs. in presence of transition metal salts)  
 RN 37517-28-5 CAPLUS  
 CN D-Streptamine, O-3-amino-3-deoxy- $\alpha$ -D-glucopyranosyl-(1 $\rightarrow$ 6)-O-[6-amino-6-deoxy- $\alpha$ -D-glucopyranosyl-(1 $\rightarrow$ 4)]-N1-[(2S)-4-amino-2-hydroxy-1-oxobutyl]-2-deoxy- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 39831-55-5 CAPLUS  
 CN D-Streptamine, O-3-amino-3-deoxy- $\alpha$ -D-glucopyranosyl-(1 $\rightarrow$ 6)-O-[6-amino-6-deoxy- $\alpha$ -D-glucopyranosyl-(1 $\rightarrow$ 4)]-N1-[(2S)-4-amino-2-hydroxy-1-oxobutyl]-2-deoxy-, sulfate (1:2) (CA INDEX NAME)

CM 1


CRN 37517-28-5  
CMF C22 H43 N5 O13

Absolute stereochemistry. Rotation (-).



CM 2

CRN 7664-93-9  
CMF H2 O4 S




L6 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 1986:61022 CAPLUS  
DOCUMENT NUMBER: 104:61022  
TITLE: The synthesis and characterization of polyene complexes with divalent metal ions: magnesium(II), calcium(II), nickel(II), copper(II) and zinc(II)  
AUTHOR(S): Beezer, Anthony E.; O'Brien, Paul; Sham, Wai L.  
CORPORATE SOURCE: Royal Holloway Bedford New Coll., Univ. London, Egham/Surrey, TW20 0EX, UK  
SOURCE: Inorganica Chimica Acta (1985), 108(2), 117-22  
CODEN: ICHAA3; ISSN: 0020-1693  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
AB Divalent metal ion (Mg, Ca, Zn, Cu, Ni) complexes of nystatin and amphotericin B (polyene antibiotics) were prepared as solids. The stoichiometry of the complexes was established. IR and ESR investigations indicate the metal-ligating sites in the polyene mols. The existence of such complexes is discussed in the light of polyene mode-of-action theories.  
IT 1397-89-3DP, magnesium and transition metal complexes


34786-70-4DP, magnesium and transition metal complexes  
 100101-96-0P 100101-97-1P 100101-98-2P  
 100101-99-3P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)  
 RN 1397-89-3 CAPLUS  
 CN Amphotericin B (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A





PAGE 1-B




RN 34786-70-4 CAPLUS  
 CN 14,39-Dioxabicyclo[33.3.1]nonatriaconta-19,21,25,27,29,31-hexaene-36-carboxylic acid, 33-[(3-amino-3,6-dideoxy- $\beta$ -D-mannopyranosyl)oxy]-1,3,4,7,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-, (1S,3R,4R,7R,9R,11R,15S,16R,17R,18S,19E,21E,25E,27E,29E,31E,33R,35S,36R,37S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.




RN 100101-96-0 CAPLUS

CN Nystatin A1, calcium salt (1:1) (9CI) (CA INDEX NAME)



● Ca


RN 100101-97-1 CAPLUS  
CN Nystatin A1, calcium salt (2:1) (9CI) (CA INDEX NAME)




● 1/2 Ca

RN 100101-98-2 CAPLUS  
CN Amphotericin B, calcium salt (1:1) (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



● Ca




RN 100101-99-3 CAPLUS


CN Amphotericin B, calcium salt (2:1) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



● 1/2 Ca



L6 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1985:415963 CAPLUS

DOCUMENT NUMBER: 103:15963

TITLE: Dimeric compounds of biochemical significance: I. Synthetic investigations of the macrocyclic tetraazaannulene hydrogen<sub>2</sub>[14]12eneN<sub>4</sub> and its nickel(II) complex. II. Synthesis of potential DNA bisintercalation reagents incorporating the antitumor antibiotic daunomycin and platinum(II) complexes of terpyridine

AUTHOR(S): Place, David Allen

CORPORATE SOURCE: Syracuse Univ., Syracuse, NY, USA


SOURCE: (1984) 237 pp. Avail.: Univ. Microfilms

Int., Order No. DA8501719

From: Diss. Abstr. Int. B 1985, 45(11), 3501-2

DOCUMENT TYPE: Dissertation  
 LANGUAGE: English  
 AB Unavailable  
 IT 20830-81-3DP, derivs., platinum complexes with terpyridine  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of, as potential DNA bisintercalation reagents)  
 RN 20830-81-3 CAPLUS  
 CN 5,12-Naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy- $\alpha$ -L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)- (CA INDEX NAME)

Absolute stereochemistry.




L6 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 1982:69350 CAPLUS  
 DOCUMENT NUMBER: 96:69350  
 TITLE: Chemical conversion of nucleosides in the sugar portion  
 AUTHOR(S): Ueda, Tohru; Shutoh, Satoshi; Inoue, Hideo  
 CORPORATE SOURCE: Fac. Pharm. Sci., Hokkaido Univ., Sapporo, 060, Japan  
 SOURCE: Nucleic Acids Symposium Series (1981), 9, 91-4  
 CODEN: NACSD8; ISSN: 0261-3166  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Nucleosides modified in the sugar portion, e.g., I and II, were prepared. Thus, 5'-deoxy-5'-bromo-2',3'-O-isopropylidene-5-chlorouridine on treatment with Bu<sub>3</sub>SnH cyclized to III, which on treatment with EtO- followed by deacetonation gave I. Ring contraction of 3'-amino-3'-deoxy- $\beta$ -D-glucopyranosyluracil by HNO<sub>2</sub> gave IV, which was converted to II.  
 IT 80647-00-3P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and reaction of, with nitrous acid)  
 RN 80647-00-3 CAPLUS  
 CN 2,4(1H,3H)-Pyrimidinedione, 1-(3-amino-6-O-benzoyl-2,3-dideoxy- $\beta$ -D-arabino-hexopyranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 80646-96-4P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation and ring-contraction of, by nitrous acid)

RN 80646-96-4 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-(3-amino-2,3-dideoxy- $\beta$ -D-arabino-hexopyranosyl)- (9CI) (CA INDEX NAME)

## Absolute stereochemistry.



L6 ANSWER 15 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1978:529886 CAPLUS

DOCUMENT NUMBER: 89:129886

## TITLE: Selective blocking of amino groups

INVENTOR(S): Nagabhushan, Tattanahalli L.; Cooper, Alan; Turner, William N.

PATENT ASSIGNEE(S): Scherico Ltd., Switz.

SOURCE: Ger. Offen., 85 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 2

#### PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2726712	A1	19771222	DE 1977-2726712	19770614 <--
DE 2726712	C2	19870619		
US 4136254	A	19790123	US 1976-697297	19760617 <--
CH 639979	A5	19831215	CH 1977-7232	19770613 <--
DK 7702632	A	19771218	DK 1977-2632	19770614 <--
DK 165451	B	19921130		
DK 165451	C	19930413		
SE 7706872	A	19780206	SE 1977-6872	19770614 <--
SE 447481	B	19861117		
SE 447481	C	19870226		
FR 2374331	A1	19780713	FR 1977-18225	19770614 <--
FR 2374331	B1	19810731		

GB 1575982	A	19801001	GB 1977-24812	19770614 <--
IL 52318	A	19810629	IL 1977-52318	19770614 <--
DE 2760317	C2	19871126	DE 1977-2760317	19770614 <--
DE 2759974	C2	19880526	DE 1977-2759974	19770614 <--
BE 855704	A1	19771215	BE 1977-178456	19770615 <--
NL 7706596	A	19771220	NL 1977-6596	19770615 <--
NL 177014	B	19850218		
NL 177014	C	19850716		
JP 52153944	A	19771221	JP 1977-70946	19770615 <--
JP 55049586	B	19801212		
ES 459791	A1	19780816	ES 1977-459791	19770615 <--
CA 1265130	A1	19900130	CA 1977-280577	19770615 <--
HU 182050	B	19831228	HU 1977-SC610	19770616 <--
HU 24887	A2	19830428		
FR 2395277	A1	19790119	FR 1978-9709	19780331 <--
FR 2395277	B1	19811120		
JP 55069519	A	19800526	JP 1979-126321	19790929 <--
JP 62027073	B	19870612		
JP 55069598	A	19800526	JP 1979-126322	19790929 <--
JP 61021558	B	19860527		
JP 55076895	A	19800610	JP 1979-126323	19790929 <--
JP 58022160	B	19830506		
JP 61027997	A	19860207	JP 1984-230025	19841031 <--
JP 01032232	B	19890629		
SE 469131	B	19930517	SE 1986-1074	19860307 <--
SE 469131	C	19930909		

PRIORITY APPLN. INFO.:

US 1976-697297 A 19760617

AB Streptamine-containing antibiotics were selectively acylated via their complexes with divalent salts of Cu, Ni, Co, or Cd. Thus 2.9 mmole sisomycin was treated with 45 mmole Cu(OAc)<sub>2</sub> and the complex treated with 9.3 mmole Ac<sub>2</sub>O followed by decomposition of acetylated complex with H<sub>2</sub>S to give 76% 3,2',6'-tri-N-acetylsisomycin. This latter compound was reductively alkylated with MeCHO and NaBH<sub>3</sub>CN to give 70% 3,2',6'-tri-N-acetyl-1-N-ethylsisomycin, which was deacetylated with NaOH to 90% 1-N-ethylsisomycin. Verdamycin, gentamycins C1A, B, C2, karamycin A, and dihydrostreptomycin underwent similar reactions.


IT 66567-24-6P 66567-34-8P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 66567-24-6 CAPLUS


CN D-Streptamine, O-3-amino-3-deoxy- $\alpha$ -D-glucopyranosyl-(1 $\rightarrow$ 6)-O-[6-deoxy-6-[(phenylmethoxy)carbonyl]amino]- $\alpha$ -D-glucopyranosyl-(1 $\rightarrow$ 4)]-2-deoxy-N3-[(phenylmethoxy)carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 66567-34-8 CAPLUS  
 CN D-Streptamine, O-3-amino-3-deoxy- $\alpha$ -D-glucopyranosyl-(1 $\rightarrow$ 6)-O-[6-deoxy-6-[(phenylmethoxy)carbonyl]amino]- $\alpha$ -D-glucopyranosyl-(1 $\rightarrow$ 4)-2-deoxy-N1-[2-hydroxy-1-oxo-4-[(phenylmethoxy)carbonyl]aminobutyl]-N3-[(phenylmethoxy)carbonyl]-, (S)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

— CH<sub>2</sub> — Ph

L6 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 1976:425414 CAPLUS  
 DOCUMENT NUMBER: 85:25414  
 TITLE: Complexes of antifungal polyene antibiotics  
 INVENTOR(S): Aszalos, Adorjan; Vandeputte, John  
 PATENT ASSIGNEE(S): E. R. Squibb and Sons, Inc., USA  
 SOURCE: U.S., 3 pp.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3957754	A	19760518	US 1975-540750	19750113 <--
US 3879374	A	19750422	US 1970-100492	19701221 <--
CA 964649	A1	19750318	CA 1971-129979	19711213 <--
GB 1386087	A	19750305	GB 1971-58042	19711214 <--
AU 7137112	A	19730628	AU 1971-37112	19711220 <--
FR 2118982	A5	19720804	FR 1971-45947	19711221 <--
FR 2118982	B1	19751010		
CH 554171	A	19740930	CH 1971-18673	19711221 <--

PRIORITY APPLN. INFO.: US 1970-100492 A3 19701221  
 AB Polyene antibiotics are complexed with a polyvalent cation in the presence of an aliphatic alc. and the resultant complexes are useful orally as antifungal agents. E.g., nystatin (2850 g) was added to FeCl<sub>3</sub>.6H<sub>2</sub>O (273

g) dissolved in MeOH, the pH was adjusted to 5.4 with methanolic NaOH, and the ferric nystatin precipitated by adding Et<sub>2</sub>O or EtOAc. The ferric nystatin had an in vitro activity equal to nystatin.

IT 1405-32-9DP, Amphotericin A, tin complex 1405-90-9DP,  
Amphotericin B, 8,9-dideoxy-10-hydroxy-7-oxo-, cerium complex

13058-67-8DP, Lucensomycin, copper complex

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study); PREP (Preparation)  
(preparation of, as fungicide)


RN 1405-32-9 CAPLUS

CN Amphotericin B, 28,29-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 1405-90-9 CAPLUS

CN Amphotericin B, 8,9-dideoxy-10-hydroxy-7-oxo- (CA INDEX NAME)



RN 13058-67-8 CAPLUS  
 CN 6,11,28-Trioxatricyclo[22.3.1.05,7]octacosa-8,14,16,18,20-pentaene-25-carboxylic acid, 22-[(3-amino-3,6-dideoxy-β-D-mannopyranosyl)oxy]-12-butyl-1,3,26-trihydroxy-10-oxo- (CA INDEX NAME)




L6 ANSWER 17 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 1975:43683 CAPLUS  
 DOCUMENT NUMBER: 82:43683  
 TITLE: Aminoglycoside antibiotics. VIII. Synthesis and activity of 4'-deoxykanamycin A  
 Naito, Takayuki; Nakagawa, Susumu; Abe, Yoshio; Fujisawa, Kei-ichi; Kawaguchi, Hiroshi  
 Bristol-Banyu Res. Inst. Ltd., Tokyo, Japan  
 Journal of Antibiotics (1974), 27(11), 838-50  
 CODEN: JANTAJ; ISSN: 0021-8820  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 GI For diagram(s), see printed CA Issue.  
 AB 4'-Deoxykanamycin A (I) was prepared from 6'-N-benzyloxycarbonylkanamycin A via N,O-polyblocked derivs. with a free OH on C'-4, which were prepared either by cleavage of the 4',6'-cyclic carbamate to give the 6'-N-carbethoxy derivative or by O → N acetyl migration from C-4' to the 6' amino group. Most of the *Pseudomonas* strains tested were sensitive to I with min. inhibitory concentration 6.3-25 mcg/ml, in comparison to kanamycin A with ≥100 mcg/ml. I also inhibits the resistant organisms which produce neomycin-kanamycin phosphotransferase II.  
 IT 54549-00-7P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(preparation and biol. activity of)

RN 54549-00-7 CAPLUS

CN D-Streptamine, O-3-amino-3-deoxy- $\alpha$ -D-glucopyranosyl-(1 $\rightarrow$ 6)-O-[6-amino-4,6-dideoxy- $\alpha$ -D-xylo-hexopyranosyl-(1 $\rightarrow$ 4)]-2-deoxy-(9CI) (CA INDEX NAME)



	SINCE FILE ENTRY	TOTAL SESSION
COST IN U.S. DOLLARS		
FULL ESTIMATED COST	95.85	268.16
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-12.48	-12.48

FILE 'STNGUIDE' ENTERED AT 18:00:39 ON 07 NOV 2007  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.  
LAST RELOADED: Nov 2, 2007 (20071102/UP).

=> d his

(FILE 'HOME' ENTERED AT 17:57:34 ON 07 NOV 2007)

FILE 'REGISTRY' ENTERED AT 17:57:45 ON 07 NOV 2007

L1 STRUCTURE uploaded  
L2 50 S L1  
L3 8649 S L1 FULL

FILE 'CAPLUS' ENTERED AT 17:58:15 ON 07 NOV 2007

L4 3550 S L3/PREP FULL  
L5 3013 S L4 AND PY<2003  
L6 17 S L5 AND NICKEL

FILE 'STNGUIDE' ENTERED AT 18:00:39 ON 07 NOV 2007

	SINCE FILE ENTRY	TOTAL SESSION
COST IN U.S. DOLLARS		
FULL ESTIMATED COST	1.50	269.66
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-12.48

STN INTERNATIONAL LOGOFF AT 18:15:55 ON 07 NOV 2007